^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sovleplenib (HMPL-523)

    i
    Other names: HMPL-523, HMPL 523, HMPL523
    Associations

    News

    Trials
    Company:
    Hutchmed
    Drug class:
    SYK inhibitor
    Related drugs:
    Associations

    News

    Trials
    22d
    The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=48, Recruiting, Hutchmed | Not yet recruiting --> Recruiting
    Enrollment open
    |
    sovleplenib (HMPL-523)
    2ms
    The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Hutchmed
    New P1 trial
    |
    sovleplenib (HMPL-523)
    3ms
    An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Hutchmed | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    sovleplenib (HMPL-523)
    4ms
    Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors. (PubMed, Haematologica)
    Sovleplenib showed antitumor activity in relapsed/refractory B-cell lymphoma with acceptable safety. Further studies are warranted.
    P1 data • Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    sovleplenib (HMPL-523)
    6ms
    Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), An Orally Available Syk Inhibitor. (PubMed, J Pharmacol Exp Ther)
    Inhibition of Syk could provide a novel therapeutic approach for autoimmune diseases and hematologic malignancies. The manuscript describes the preclinical pharmacology characterization of sovleplenib, a novel Syk inhibitor, in enzymatic and cellular assays in vitro and several murine autoimmune disease models in vivo.
    Preclinical • Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    sovleplenib (HMPL-523)
    over2years
    Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma (ASH 2021)
    The dose expansion phase of the study will evaluate safety and efficacy in patients with multiple subtypes of B-cell and T-cell lymphoma at the RP2D of 700 mg. Updated safety, PK, and anti-tumor activity will be presented.
    Clinical • P1 data
    |
    SYK (Spleen tyrosine kinase)
    |
    sovleplenib (HMPL-523)
    almost4years
    [VIRTUAL] A phase I study of HMPL-523, a small molecule, selective inhibitor of spleen tyrosine kinase, inpatients with relapsed or refractory lymphoma (AACR-II 2020)
    Ongoing global studies are still open and enrolling patients with R/R lymphoma. Validated data / results from this study will be made available at the end of dose escalation and or at the conclusion of dose expansion stage.
    Clinical • P1 data
    |
    SYK (Spleen tyrosine kinase)
    |
    sovleplenib (HMPL-523)